About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer

by Dr. Trupti Shirole on February 20, 2015 at 12:32 AM
 Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer

A new study has revealed that a combination of chemotherapy and treatment with two drugs, Perjeta and Herceptin, lengthens survival of patients with HER2-positive metastatic breast cancer by an average of nearly 16 months.

Lead researcher Dr. Sandra M. Swain said, "We've never seen results like this before in HER2-positive metastatic breast cancer. This unprecedented data gives patients with an aggressive disease hope to live a longer, better life."

Advertisement

During the study, patients received either Perjeta with Herceptin and chemotherapy or placebo with Herceptin and chemotherapy in the control group. The median overall survival for patients who received the Perjeta with Herceptin and chemotherapy was 56.5 months, compared with 40.8 months for those in the control group, a difference of 15.7 months. The study also revealed that the patients' cancer did not get worse for 6.3 months longer in the Perjeta group.

The study is published in the 'New England Journal of Medicine'.

Source: Medindia
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

Personalized Vaccine and T Cell Therapy for Ovarian Cancer Patients
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Kinase-Targeted Therapy Revolutionizes Colorectal Cancer Care
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
Novel Photo-Oxidation Therapy Holds Promise for Anticancer Treatment
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 Genes Linked to Aggressive Prostate Cancer
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Link Between Poor Oral Health and Head & Neck Cancer Survival Uncovered
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Perjeta With Herceptin and Chemotherapy Lengthens Survival of Patients With HER2-Positive Metastatic Breast Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests